<DOC>
	<DOCNO>NCT01808651</DOCNO>
	<brief_summary>This study evaluate safety effectiveness fluoxetine flexible dosing treatment MDD adult Japanese participant . Participants complete short-term treatment phase Study B1Y-JE-HCLV ( NCT # : NCT01808612 ) allow enroll study , receive fluoxetine treatment additional 52 week .</brief_summary>
	<brief_title>A Study Fluoxetine Major Depressive Disorder ( MDD ) Long-Term Dosing</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Have complete Study B1YJEHCLV ( NCT # : NCT01808612 ) Agree abstain sexual activity use reliable method birth control Significant suicidal risk Have current previous diagnosis bipolar disorder , psychotic depression , schizophrenia psychotic disorder , anorexia , bulimia , obsessive compulsive disorder , posttraumatic stress disorder Have history substance abuse dependence within past 6 month , exclude caffeine nicotine Need use thioridazine pimozide study Have positive urine drug screen drug abuse potential Female participant either pregnant , nursing , recently give birth , male participant plan partner become pregnant Have frequent severe allergic reaction multiple medication Have serious unstable medical illness condition , psychological condition Participants deem ineligible investigator subinvestigator reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>